Loading patent…
AssigneeOptigenex, Inc.
InventorRonald W. Pero
Estimating the term…
A method for isolating the bioactive component of the water-soluble extract of Uncaria tomentosa known as C-MED-100®, comprising (i) precipitating the spray drying carrier from C-MED-100®; (ii) using the resulting C-MED-100® to obtain a spotting mixture for thin layer chromatography (TLC); (iii) spotting the C-MED-100® spotting mixture on pre-run TLC plates and eluting the plates to obtain the fluorescing band with Rf=0.2-0.3; (iv) scraping off the Rf=0.2-0.3 band, eluting it in ammonia and freeze drying the eluted band to form a powder; and (v) extracting the powder with methanol to remove solubilized silica gel, concentrating the methanol solution and crystalizing the concentrated solution to obtain the bioactive component. The isolated bioactive component is a quinic acid analog, preferably quinic acid lactone. A pharmaceutical composition comprising a pharmaceutically effective amount of the bioactive component and a nontoxic inert carrier or diluent. The bioactive component may be used to enhance immune competency, treat disorders associated with the immune system, inhibit the inflammatory response, treat disorders associated with the inflammatory response, enhance the anti-tumor response, and treat disorders associated with the response to tumor formation and growth, all in mammals.
A method for isolating a bioactive component of a water soluble extract of a botanical species, wherein said extract exhibits UV maxima at approximately 199 nm, is stable to temperatures less than 100° C. for 24 hours and sterilization by autoclaving for up to at least 20 minutes at approximately 121° C., maintains biological activity for at least 6 months when frozen in liquid form at approximately −20° C. and consist essentially of molecules having a molecular weight of up to approximately 12,000 comprising:
A bioactive component of a water soluble extract of a botanical species wherein said bioactive component consists essentially of one or more carboxy alkyl esters (CAEs).
A pharmaceutical composition comprising:
Dependencies are inferred from the claim text.